Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen

Der Knochen stellt einen häufigen Metastasierungsort solider Tumoren dar. Knochenmetastasen können starke Schmerzen sowie skelettbezogene Komplikationen verursachen, die zu einer erhöhten Mortalität und Morbidität sowie einer erheblichen Beeinträchtigung der Lebensqualität führen.

• Publication year

  2023

• Venue

  Frauenheilkunde up2date

• Publication date

  2023-02-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/a-1931-5820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer-Associated Hypercalcemia.

  2022cited by this paper
• Evaluation and management of Cauda Equina Syndrome.

  2021cited by this paper
• Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review

  2020cited by this paper
• Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study

  2020cited by this paper
• Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

  2020influential reference
• Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.

  2020influential reference
• Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis

  2020cited by this paper
• The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn

  2020influential reference
• BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES.

  2020influential reference
• Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.

  2019cited by this paper
• Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  2019cited by this paper
• De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

  2019influential reference
• Pharmacology of bisphosphonates.

  2019cited by this paper
• Decision Making in Patients With Metastatic Spine. The Role of Minimally Invasive Treatment Modalities

  2019cited by this paper
• Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.

  2019influential reference
• Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines.

  2018cited by this paper
• US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.

  2018cited by this paper
• Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis

  2018cited by this paper
• Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management.

  2018influential reference
• Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial

  2017influential reference
• Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis.

  2017cited by this paper
• Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice

  2017cited by this paper
• Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.

  2017cited by this paper
• Tramadol with or without paracetamol (acetaminophen) for cancer pain.

  2017cited by this paper
• Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

  2017cited by this paper
• Bisphosphonates and other bone agents for breast cancer.

  2017influential reference
• Oral paracetamol (acetaminophen) for cancer pain.

  2017cited by this paper
• Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project

  2017cited by this paper
• Cancer-Related Hypercalcemia.

  2016cited by this paper
• Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.

  2016cited by this paper
• Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic

  2016cited by this paper
• Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

  2015influential reference
• Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer.

  2014cited by this paper
• Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

  2014cited by this paper
• Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

  2014influential reference
• Pain and nociception: mechanisms of cancer-induced bone pain.

  2014cited by this paper
• Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

  2013cited by this paper
• Pain outcomes in patients with advanced breast cancer and bone metastases

  2013cited by this paper
• Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

  2013cited by this paper
• Effects of RANKL-Targeted Therapy in Immunity and Cancer

  2013cited by this paper
• Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

  2012cited by this paper
• Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

  2012cited by this paper
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• Characterization of cancer-induced bone pain: an exploratory study

  2011cited by this paper
• Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

  2011influential reference
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer.

  2010cited by this paper
• Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

  2009cited by this paper
• Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.

  2008cited by this paper
• Bisphosphonate nephrotoxicity.

  2008influential reference
• Management of the adverse effects associated with intravenous bisphosphonates.

  2006cited by this paper
• Hypercalcemia Associated with Cancer

  2005cited by this paper
• Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

  2005influential reference
• Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

  2004cited by this paper
• Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

  2004cited by this paper
• Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

  2004influential reference
• Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

  2003cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

  2001cited by this paper
• Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

  2000cited by this paper
• Oral clodronate in breast cancer patients with bone metastases: a randomized study

  1999cited by this paper
• Malignant bone pain: pathophysiology and treatment

  1996cited by this paper
• Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.

  1994cited by this paper
• Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

  1993cited by this paper
• Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

  1993cited by this paper
• Oncotargets and Therapy Dovepress

  year unknowninfluential reference

• No citing papers are available for this paper.